Analysts expect Antares Pharma Inc (NASDAQ:ATRS) to announce earnings of ($0.02) per share for the current quarter, Zacks reports. Five analysts have provided estimates for Antares Pharma’s earnings, with the lowest EPS estimate coming in at ($0.03) and the highest estimate coming in at ($0.01). Antares Pharma posted earnings of ($0.03) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The business is scheduled to report its next earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Antares Pharma will report full year earnings of ($0.10) per share for the current financial year, with EPS estimates ranging from ($0.13) to ($0.07). For the next financial year, analysts forecast that the firm will report earnings of $0.07 per share, with EPS estimates ranging from $0.00 to $0.18. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). Antares Pharma had a negative return on equity of 64.96% and a negative net margin of 35.53%. The firm had revenue of $14.16 million for the quarter, compared to analyst estimates of $13.70 million.
ATRS has been the topic of several research analyst reports. BidaskClub raised shares of Antares Pharma from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 24th. ValuEngine raised shares of Antares Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, August 8th. Finally, HC Wainwright set a $4.00 target price on shares of Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, August 8th.
In related news, Director Jacques Gonella sold 49,507 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $3.09, for a total value of $152,976.63. Following the sale, the director now directly owns 9,985,848 shares of the company’s stock, valued at $30,856,270.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert F. Apple sold 43,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $3.75, for a total transaction of $161,250.00. Following the completion of the transaction, the chief executive officer now owns 1,573,562 shares in the company, valued at approximately $5,900,857.50. The disclosure for this sale can be found here. Insiders sold 343,000 shares of company stock worth $1,088,250 over the last three months. Corporate insiders own 12.20% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. purchased a new position in Antares Pharma in the first quarter valued at approximately $1,959,000. JPMorgan Chase & Co. raised its holdings in Antares Pharma by 533.6% in the first quarter. JPMorgan Chase & Co. now owns 448,634 shares of the specialty pharmaceutical company’s stock valued at $987,000 after buying an additional 377,824 shares during the period. United Services Automobile Association raised its holdings in Antares Pharma by 1,453.0% in the second quarter. United Services Automobile Association now owns 405,261 shares of the specialty pharmaceutical company’s stock valued at $21,147,000 after buying an additional 379,166 shares during the period. Mycio Wealth Partners LLC purchased a new position in Antares Pharma in the second quarter valued at approximately $6,278,000. Finally, Wells Fargo & Company MN raised its holdings in Antares Pharma by 21.5% in the first quarter. Wells Fargo & Company MN now owns 1,933,469 shares of the specialty pharmaceutical company’s stock valued at $4,253,000 after buying an additional 342,062 shares during the period. Hedge funds and other institutional investors own 38.93% of the company’s stock.
Shares of ATRS traded up $0.04 during mid-day trading on Friday, hitting $3.21. The company had a trading volume of 706,357 shares, compared to its average volume of 1,527,002. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.89 and a current ratio of 2.33. Antares Pharma has a 1-year low of $1.58 and a 1-year high of $4.09. The stock has a market capitalization of $516.39 million, a PE ratio of -29.18 and a beta of 0.34.
Antares Pharma Company Profile
Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
See Also: Google Finance Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.